



Understanding Practice in the National Clinical Audit and Patient Outcomes Programme (UPCARE) - Workstream section

0.01 Programme name National Cancer Audit Collaborating Centre

0.02 Workstream name National Metastatic Breast Cancer Audit (NAoMe)

0.1 Contract status Ongoing

0.2 Audit or non-audit Audit

0.3 HQIP commissioned* Yes

0.41 HQIP AD CR

0.42 HQIP PM SW

1.0 Included in current NHS Quality Accounts* Yes

1.1a Geographical coverage - HQIP agreement* England; Wales

1.2a Topic - please select which ONE of the following best describes the topic area for the programme or workstream. If more than one apply, please select 'Other' and add comment to the next question.* Cancer

1.3a Healthcare setting* NHS secondary or tertiary care

1.4 Inclusion and exclusion criteria* The National Audit of Metastatic Breast Cancer (NAoMe) aims to report on patients diagnosed with metastatic breast cancer in NHS hospitals in England & Wales. The NAoMe builds on the work of the National Audit of Breast Cancer in Older Patients (NABCOP) and for the first time will include women and men of all ages with metastatic breast cancer.

1.5 Methods of data submission* Extraction from existing data source(s)

1.6a 2023/24 data submission closes - please indicate date, series of dates or frequency.* 31/3/2024 (please note data submission is continuous)

1.6b 2024/25 data submission closes - please indicate date, series of dates or frequency.*	31/3/2025 (please note data submission is continuous)
1.7 Data flow diagram	https://www.natcan.org.uk/resources/natcan-dataflow-diagram/
1.8 Data quality & analysis plan	Initial information on this can be found in the NAOme Scoping Report (https://www.natcan.org.uk/audits/metastatic-breast/reports/naome-scoping-document/).
	See Healthcare Improvement Plan
	See State of the Nation 2025 Methodology Supplement
1.9a Link to the outlier policy*	See follow in the Healthcare Improvement Plan
2.1 Outcome measures	See Healthcare Improvement Plan
2.2 Process measures	See Healthcare Improvement Plan
2.3 Organisational measures	See Healthcare Improvement Plan
2.4 Patient reported outcome measures	See Healthcare Improvement Plan
2.5 Patient reported experience measures	See Healthcare Improvement Plan
2.6a Do measures align with any of the following sources of evidence (select all that apply)	Other (please describe in next question); NICE clinical guideline; NICE quality standard
2.6b Evidence supplemental information	As per page 11 of the NAOme Healthcare Improvement Plan: The measures for the NAOme align with the following sources of evidence: <ul style="list-style-type: none"> • NICE Quality Standard 12* - Quality Statement 5, EUSOMA/ABC** - Breast cancer outcomes are improved when care is directed by a multi-disciplinary team. • NICE Quality Standard 12 - Quality Statement 4, NICE CG81*** recommendation 1.1, EUSOMA/ABC - Confirmation of a diagnosis of metastatic breast cancer. • EUSOMA, ABC - Endocrine therapy should be first line for ER positive/HER2-negative disease. • EUSOMA/ABC - Anti-HER2 therapy should be offered as a first line to all patients with HER2-positive MBC. • EUSOMA/ABC - Chemotherapy can be utilised for many indications in MBC dependant on tumour biology.

- NICE CG81**** recommendation 1.5, EUSOMA/ABC - Management of bone metastases should involve a bone-modifying agent.
- NICE CG81 recommendation 1.5, EUSOMA/ABC - Radiotherapy utilisation in MBC following surgery.
- NICE Quality Standard 12 - Quality Statement 6, NICE CG81 recommendation 1.4, EUSOMA/ABC - Assigning key workers to people with locally advanced or metastatic breast cancer.
- National Confidential Enquiry into Patient and Outcome Death (NCEPOD) and National Patient Safety Agency reports – highlighting the need for improvements in the quality and safety of systemic anti-cancer therapy.

* NICE. Breast Cancer. 2011; Available from: <https://www.nice.org.uk/guidance/qs12>.

** Cardoso, F., et al., European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care. Eur J Cancer, 2023. 187: p. 105-113.

*** NICE Advanced breast cancer: diagnosis and treatment (CG81). 2009.

**** World Health Organization Global Breast Cancer Initiative Implementation Framework: Assessing, Strengthening and Scaling-Up of Services for the Early Detection and Management of Breast Cancer. 2023.

3.1 Results visualisation	Annual report; Patient report; Interactive online portal (run charts available); Static data files; Other
3.2a Levels of reporting*	National; Trust or health board; NHS region or other geographic area; Cancer alliance
3.3 Timeliness of results feedback	Within 2 years
3.4 Link to dynamic reporting*	https://www.natcan.org.uk/audits/metastatic-breast/reports-2/
4.01 2023/24 Dataset covers the period FROM/TO (within financial year 01/04 to 31/03)*	01/04/2023 - 31/03/2024
4.02 2024/25 Dataset covers the period FROM/TO (within financial year 01/04 to 31/03)*	01/04/2024 - 31/03/2025
4.03 2025/26 Dataset covers the period FROM/TO (within financial year 01/04 to 31/03)*	01/04/2025 - 31/03/2026
4.10 Dataset #1 name	NAoMe Dataset
4.11 Dataset #1 type	Clinical audit
4.12 Dataset #1 population coverage*	All eligible patients

4.15 Dataset #1 use of existing national datasets	Cancer outcomes and services dataset (COSD); Cancer network information system Cymru (CaNISC); Hospital episode statistics (HES); Office for National Statistics (ONS); Patient episode database for Wales (PEDW); Radiotherapy dataset (RTDS); Systemic anticancer treatment (SACT); Cancer waiting times (CWT); Cancer patient experience survey (CPES)
5.00 When was your healthcare quality improvement plan (referred to as a QI Plan) last reviewed? Please upload under 'Files' below using the HQIP naming convention (click on response to see pop-up help text).	05/09/2025
5.11 Please add the hyperlink to where your clinical performance indicators (referred to as metrics) are published on your project website.*	https://www.natcan.org.uk/audits/metastatic-breast/quality-improvement/ ; https://www.natcan.org.uk/wp-content/uploads/2025/07/NAoMe_Metrics_Table_240924_V1.xlsx
5.20 National report publication date (within calendar year 01/01 - 31/12/2023)*	29/11/2023 - Scoping Document
5.21 Published/planned national report publication date (within calendar year 01/01 - 31/12/2024)*	12/09/2024
5.22 Planned national report publication date (within calendar year 01/01 - 31/12/2025)*	11/09/2025
6.0 Please add the most recent date that you have reviewed and updated an online version of UPCARE Workstream section(s) on your project's website (click into the response to see pop-up guidance).	08/01/2026
6.1 Please add a hyperlink to UPCARE Workstream section(s) on your website (click into the response to see pop-up guidance).*	https://www.natcan.org.uk/resources/naome-upcare-tool/